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Abstract
Detailed information on intrahost viral evolution in SARS‐CoV‐2 with and without
treatment is limited. Sequential viral loads and deep sequencing of SARS‐CoV‐2 from the
upper respiratory tract of nine hospitalized children, three of whom were treated with
remdesivir, revealed that remdesivir treatment suppressed viral load in one patient but
not in a second infected with an identical strain without any evidence of drug resistance
found. Reduced levels of subgenomic RNA during treatment of the second patient,
suggest an additional effect of remdesivir on viral replication. Haplotype reconstruction
uncovered persistent SARS‐CoV‐2 variant genotypes in four patients. These likely arose
from within‐host evolution, although superinfection cannot be excluded in one case.
Although our dataset is small, observed sample‐to‐sample heterogeneity in variant fre-
quencies across four of nine patients suggests the presence of discrete viral populations
in the lung with incomplete population sampling in diagnostic swabs. Such
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compartmentalization could compromise the penetration of remdesivir into the lung,
limiting the drugs in vivo efficacy, as has been observed in other lung infections.
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1 | BACKGROUND
Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), which
causes coronavirus disease 2019 (COVID‐19), was first identified in
Wuhan, China in December 2019. On March11, 2020, the WHO de-
clared COVID‐19 a global pandemic. Since then, an estimated 50 million
people have been infected, of whom up to 2.5% have died.1 A number
of studies have assessed nasal and oropharyngeal viral load data from
longitudinally sampled SARS‐CoV‐2‐infected patients. Their findings
reveal wide variations in viral load at presentation.2,3 However, milder
disease and clinical recovery are associated with lower and declining
viral load respectively, pointing to its potential use as a biomarker for
antiviral drug response. Remdesivir, an RNA‐dependent‐RNA poly-
merase (RdRp) inhibitor, has been shown in one large randomized clin-
ical trial (RCT) to be effective against SARS‐CoV‐2, although another
large study, showed no clinical benefit and smaller studies have shown
limited or no impact on clinical recovery.2,4–8Where clinical trial data are
lacking or contradictory we have previously used deep pathogen se-
quencing, mutational analysis, and evolutionary modeling to gain insight
into the impact of repurposed drugs, including RdRp inhibitors similar to
remdesivir, on serious respiratory RNA viral infections in hospitalized
patients.9,10 These studies have revealed drug‐related mutational sig-
natures, evidence of viral compartmentalization in the lung and pre-
viously unrecognized synergy between combination therapies
associated with changes in viral loads and improved clinical outcomes.
Here we report the application of similar methods in a personalized
medicine approach to investigating the impact of remdesivir on SARS‐
CoV‐2 within an individual and to evaluate potential biomarkers that can
be used to monitor clinical efficacy. The data provide further insights
into fundamental questions of SARS‐CoV‐2 evolution and coinfection.
2 | METHODS
2.1 | Sample collection and viral sequencing
Nasopharyngeal swab samples were collected and tested for SARS‐
CoV‐2. Full‐length SARS‐CoV‐2 genome sequences were obtained
from all positive samples using SureSelectXT target enrichment and
Illumina sequencing. For each patient, a unique patient reference was
generated by mapping the remaining reads of the first sample to the
SARS‐CoV‐2 reference genome (NC_045512) from GenBank using
bwa‐mem.11 Reads from the subsequent samples of the same patient
were mapped to this patient reference. Consensus sequences were
aligned using MAFFT.12 Only genomes with more than 80% genome
coverage and a mean read depth of 100 or above were included in
downstream analysis.
2.2 | Phylogenetic analysis
The maximum likelihood tree of the alignment was constructed using
RAxML,13 with the GTR model and 1000 bootstrap replicates. All trees
were rooted on the SARS‐CoV‐2 reference genome NC_045512.
2.3 | Analysis and figure generation
Analysis was completed in R 3.6.1 using Rstudio 1.2. In general, data were
processed using the tidyverse family of packages (v1.2.1). We employed
the fisher.test in R to compare the count‐data of mutations for treated
and untreated samples across all individuals. The Mann–Whitney–
Wilcoxon test was implemented using the wilcox.test in R. We used
Pearson's and Spearman's rank correlation for correlation analysis. This
was done using the lm.test and cor.test function in the stats package in R.
2.4 | Haplotype reconstruction
Haplotypes were reconstructed using HAplotype Reconstruction Of
Longitudinal Deep Sequences (HaROLD) with default settings.14
HaROLD does not statistically support haplotypes from a single
minority variant alleles (MVAs), we therefore constructed by hand the
haplotypes for Patient B. In this case, the haplotype frequency was
taken to be that of the single MVA.
2.5 | Quantification of subgenomic RNA
We employed Periscope to detect subgenomic RNA (sgRNA).15
sgRNA is identified based on the detection of the leader sequence at
the 5ʹend (5ʹ‐AACCAACTTTCGATCTCTTGTAGATCTGTTCT‐3ʹ) of
the sequence. To optimize recovery, we excluded genomes with less
than 90% coverage and less than 100 mean read depth (MRD).
2.6 | Minority variant calling
Minority allele variants had to have a frequency of above 2% and
with a minimum of four supporting reads identified at sites with a
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read depth of ≥5 using VarScan.16 Transient MVAs, which occurred
at one time point in an individual, were discarded from the analysis.
2.7 | Structural biology
The structure of the spike protein PDB 6XR8 was visualized using
VMD. Mutations were modeled using the Swiss model.
2.8 | Study approval
We sequenced SARS‐CoV‐2 samples routinely collected for clinical
monitoring from children hospitalized for COVID‐19 in London be-
tween early March and mid‐May 2020. This study was approved by
Great Ormond Street Hospital (Clinical Audit Number #2857) and
PHE Research Ethics and Governance Group (REGG) (R&D NR0195).
3 | RESULTS
3.1 | Overview of patients
We analyzed nine hospitalized SARS‐CoV‐2 positive pediatric cases
with a mean age at the time of infection of 4.7 years old (range 0–14
years old), who were repeatedly sampled during the course of their
SARS‐CoV‐2 infection. A summary of their clinical features is shown in
Table 1. Five patients had pre‐existing comorbidities associated with
primary or secondary immunodeficiency (Table 1). Two patients (B and
C) were admitted from the community, three patients (E, F, and I) were
long‐term inpatients who had healthcare‐acquired SARS‐CoV‐2, and
four (A, D, G, and H) were transferred within days of diagnosis of testing
positive for SARS‐CoV‐2 from other hospitals for tertiary‐care treat-
ment. Of the nine patients, four (A, D, G, and H), of whom only H was
known to be immunocompromised, were admitted to the Pediatric In-
tensive Care Unit (PICU) (Figure S1). The remaining patients were cared
for in the appropriate source isolation and were not colocated during
their SARS‐CoV‐2 infection (Figure S1). Patients, A, D, and G received
8–10 days of remdesivir through a compassionate pediatric access
program. Patients A and G received 200mg loading dose followed by
100mg daily and Patient D received 5mg/kg (10mg) loading dose and
1.25mg/kg (2.5mg) once daily (Table 1).
3.2 | Viral load trajectories by cycle threshold and
clinical markers of infection
Figure 1 shows the viral polymerase chain reaction (PCR) cycle
threshold (ct) values for all nine patients for 40 days following their
first positive sample available to us. Viral RNA was measured in na-
sopharyngeal aspirate for all patients and/or upper airway secretions
for those who were intubated (Patients A, D, G, and H). Patient A also
had a bronchoalveolar lavage. In agreement with earlier studies,17 the
ct values showed a considerable day‐to‐day variation of between
0.16 and 14.4 cycle numbers (median 5.5 cycle numbers). Viral RNA
continued to be detectable for 7 to over 50 days (median 16 days)
following the first positive sample (Figure S2). Of the three patients
who received remdesivir, only Patient D had total suppression of viral
RNA during treatment followed by a rebound of the virus after
treatment cessation (Figure 1). The four ICU patients were clinically
most unwell, requiring assisted ventilation. All three remdesivir‐
treated patients showed clinical improvement after starting the drug,
associated with falls in temperature (all) and inflammatory markers
(A and G) (Figure S3). All three were weaned from conventional
ventilation before the treatment course was completed with de-
creases in oxygen requirements. In Patient D, a significant reversal of
respiratory deterioration was noted once remdesivir was started;
inhaled nitric oxide was stopped within 96 h coincident with weaning
from high frequency oscillatory to conventional ventilation. Patient
D, who alone required inotropic support, achieved hemodynamic
stability off inotropes within 5 days of starting remdesivir.
3.3 | Inter‐ and intrahost phylodynamics of
SARS‐CoV‐2
To investigate the possibility of remdesivir resistance in Patients A, D,
and G, we deep sequenced all samples as well as those from un-
treated patients for comparison (Figure 1). The sequencing metrics
for the samples are summarized in Table S1. Relative to their first
available sample, there were nine polymorphisms identified in viruses
from Patients A, H, and I, of which five were nonsynonymous with
four in the ORF1ab (nsps 1, 3, 4, 5) and one in the Spike protein, S2
subdomain (Table S2). None of the identified SNPs were sites iden-
tified as common homoplasies or those known to be susceptible to
Illumina sequencing error, none have been associated with remdesivir
resistance and none, other than spike mutation P812L, which is lo-
cated within a predicted CD4 T cell epitope, were in known or pre-
dicted immune epitopes.18–25 P812L was not predicted to alter spike
protein structure, although it is not known whether it would abrogate
T cell binding (Figure S4).18 Patient E was negative for SARS‐CoV‐2 in
consecutive samples obtained on Days 16 and 22. The virus detected
again at Days 31 and 35 was identical to all other sequences from this
patient. We observed changes in the consensus sequences between
sequential samples from Patients A, H, and I. Sequences A at time
Points 6, 7, and 8 were identical to those of samples sequenced from
patient D (Figure 2A). No evidence of laboratory contamination to
explain the identity between A and D sequences was found.
3.4 | No mutagenic signature identified for
remdesivir
In vitro studies have not shown lethal mutagenesis to be a feature of
remdesivir.26,27 To exclude nonlethal mutagenesis as a possible ex-
planation for continuing high viral RNAs despite remdesivir
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TABLE 1 Overview of patient clinical, treatment, sampling, and viral lineage data for all nine patients
Patient Gender
Age,


























3 Y [8] 12 9 B.1.1 47–49







Unknown N 0 3 B.1.1 47–49





0 N 0 5 B.2.1 47–49








1 Y [10] 22 7 B.1.1 47–50





Suspected 1 N 0 5 B.1.p16 47–49










Suspected 0 N 0 2 B.2.1 47–49
G Male 14 Unspecified 120 obese Immunocompetent Other
hospital
(04/20)
10 Y [10] 10 10 B.1.1.7 47–49
H Male 1 Black African 10.3 Hepatoblastoma Immunocompromised Other
hospital
(04/20)
Unknown N 34 13 B.1.p11 47–49
















treatment, we compared the mutational burden and patterns of
transitions and transversions in treated and untreated patients. In
accordance with current understanding of its mode of action, we
found neither an increased mutational burden in remdesivir‐treated
patients nor any evidence of associated mutational signature (-
Figures S5 and S6). We found no evidence that the proportion of
transitions and transversions distribution of mutation was dependent
on the treatment (Fisher t test, p = 0.13).
3.5 | Measurement of subgenomic RNA
To determine whether, despite stable viral ct values, remdesivir treat-
ment may have inhibited viral replication we analyzed subgenomic RNA
(sgRNA) detected by the genome sequencing using Periscope.15 Stacked
bar‐plots of the frequency of sgRNA reads per 100 000 mapped reads
(sgRPHT) for each gene and corresponding ct values for each patient are
compared in Figure 3A. Unlike previous reports, no correlation was
found between sgRPHT and ct‐values (Figure S7A).28We have excluded
Patient D from the comparative analysis below as their virus was sup-
pressed below the limit of detection during remdesivir treatment.
sgRNA levels in samples taken during remdesivir treatment for Patients
A and G were lower than in samples off treatment
(Mann–Whitney–Wilcoxon test p = 0.05) (Figure 3B). Samples 6, 7, and
8 in Patient A had mean viral ct values of 28.7 (range 28.24–29.02) with
barely detectable sgRNA despite high MRDs (3402‐6297). sgRNA was
detected in all other samples with ct values <35 bar two. A similar
tendency towards significance of remdesivir treatment on levels of
sgRPHT was shown across all patients over all time points
(Mann–Whitney–Wilcoxon test p = 0.059) (Figure S7B).
F IGURE 1 Ct trajectories of nine patients from 1st day up to 40 days post first positive. One panel per patient, red line indicates remdesivir
received, black dot is sample taken, blue circle indicates sample successfully sequenced. Orange dot indicates bronchoalveolar lavage sample
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(A)
(B)
F IGURE 2 RAxML phylogenetic trees rooted at NC_045512. (A) Tree using consensus level sequences for Patients A–I. Boxes highlight
distinct, identical sequences excluding gaps, found in Patients A, H, and I over time. Samples are labeled as [Patient][Time]. (B) Tree using
haplotype sequences for Patients A, B, H, and I and consensus levels sequences for Patients D–G for which no haplotypes are identified.
Haplotypes defining mutations are shown along the corresponding branches. Samples are labeled as Hap [number]_[Patient][Time]
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F IGURE 3 Evaluation of effect of remdesivir on levels of sgRPHT. (A) Comparison of ct values and sgRPHT over time by Patient. Stacked
bars represent sgRPHT values colored by gene. Black line represent ct values, with blue circles annotating successfully sequenced samples.
Y‐axis is days post first positive. (B) Box‐plot of sgRPHT on and off remdesivir for Patients A and G. Samples from each individual are
identified by their shape. Treated samples have low sgRPHT than untreated samples taken in the same time‐window post first positive
(Mann–Whitney–Wilcoxon test, p = 0.05). Patient D was excluded from this comparison as no sequences were available during remdesivir
treatment as viral load was below the limit of detection
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3.6 | Evidence of mixed infection
We observed changes in the consensus sequences at different
timepoints in Patients A, H and I (Figure 2A). As depicted on the tree,
no SNPS relative to reference sequence NC_045512 are shared
across all patients and neither are there any such SNPs that are un-
ique to patients admitted to ITU and/or on treatment (Table S3). To
further examine this and the identical sequences from Patients D and
A, we analyzed MVAs as outlined in the methods. A complete list of
identified polymorphisms for each sample, and corresponding fre-
quency and read support, can be found in Table S4. Patients A, B, H,
and I had well‐supported MVAs which varied in frequency over time
(Figure S8). MVAs in other patients occurred for the most part on a
single occasion or at levels less than 20% with poor read support. To
resolve possible mixed infections within each sample, we used the
haplotype reconstruction method HaROLD.14 HaROLD identified
three haplotypes for Patient A, four for Patient H, two for Patient I,
two in Patient B with one in all other patients. All identified haplo-
types are labeled as Hap_[number]_[Patient][Time]. Haplotypes
clustered phylogenetically by patient other than Hap1_A, found at
the root of the clade from Patient A, which was identical to viral
sequences from Patient D (Figure 2B). We observed no obvious
pattern of haplotype change in any of the patients, with sample‐to‐
sample variation in viral loads and haplotype abundance occurring
particularly in Patients A and H (Figure 4A).
We next investigated whether the haplotypes within Patients A, H, I,
and B were likely to represent coinfections with different viruses.29 Using
Local Lineage and Monophyly Assessment (LLAMA),30 we identified the
nearest samples to each haplotype in the global alignment on COVID‐19
Genomics UK (COG‐UK) consortia.31 The local trees identified by LLAMA
are shown in Figure S9. Comparison of haplotypes in Patients A, H, and I
with global sequences confirmed that haplotypes Hap1_A, Hap2_A,
Hap3_H, and Hap1_I were circulating independently globally as were the
single genotypes from Patients C, E, and F (Figure S9). However, haplo-
types Hap3_A, Hap1/2_B, Hap1/2_H, and Hap2_I as well as the virus
from Patient G were not represented among 61740 global sequences
available on GISAID.32 This may reflect incomplete population sampling
or the recent emergence of new lineages. Alternatively, it is possible that
some haplotypes are not currently freely circulating in the population and
possibly that the mutations they carry are deleterious as has been pos-
tulated for influenza.33 The close clustering between each of the non-
circulating viruses with other haplotypes in their cognate hosts supports
within‐host evolution (Figure S9), as opposed to coinfection with multiple
viruses as has previously been suggested.34
A possible exception to this conclusion was Patient A. It is con-
ceivable that haplotype Hap1_A, which is identical to the viral se-
quence from patient D, could have resulted from superinfection.
Patients A and D were colocated in the Intensive Care Unit (ICU)
(Figure S1). Haplotype Hap1_A was not identified in the sample taken
from Patient A before their transfer to the ICU but was detected
approximately 28 h later in a sample taken 2 h before starting re-
mdesivir (Figure 4B). However, no other healthcare‐associated
transmissions were reported in the ICU and local epidemiological
investigation suggests it to have been unlikely. Moreover, in view of
the rapid appearance of Hap1_A following transfer to ICU and the
variation in haplotype frequencies over time, it is more probable that
Hap1_A and 2_A were present in the patient's first sample but not
detected. This would support the within‐host evolution of these
three closely related strains, for one of which, Hap3_A, there is no
evidence of circulation in the population.
4 | DISCUSSION
Our comparative analysis of longitudinal samples from remdesivir‐
treated and untreated patients infected with SARs‐CoV‐2 identifies
evidence of remdesivir‐associated suppression of viral RNA and
sgRNA in vivo and uncovers the presence of mixed viral haplotypes
likely to have evolved within each host early in infection, persisting
thereafter, in some cases possibly within discrete tissue compart-
ments in the lung.
Although remdesivir may have resulted in clinical improvements
for the patients described here, only in Patient D was this accom-
panied by a fall in viral RNA levels. Viral RNA remained undetectable
until treatment was stopped, when it again rose. In Patient A, no
change in viral RNA levels occurred during remdesivir treatment;
however, SARS‐CoV‐2 sgRNA levels appear to have reduced, in-
creasing again following cessation of treatment (Figure 4). Although
sgRNA levels have been shown to have a weak association with viral
replication in in vitro culture,35 the extent to which sgRNA levels
reflect viable virus better than viral RNA remains controversial.28 Our
data samples obtained during remdesivir therapy had lower sgRNA
levels even when high viral RNA persisted (Figure 4). The samples
have good coverage and MRDs (Table S1), thus excluding RNA de-
gradation as the cause of low sgRNA. Our results mirror findings from
remdesivir study in the macaques model which showed viability in in
vitro culture of virus from upper respiratory samples is decreased and
clinical scores are improved, despite no change in viral RNA levels.36
The possibility that sgRNA, may, together with viral load, provide a
biomarker of response to remdesivir should now be explored.
We observe considerable variation in the consensus SARS‐CoV‐2
sequences obtained from four of the nine patients, which appears un-
related to remdesivir treatment. The heterogeneity is explained by the
presence of between 2 and 4 stable viral haplotypes that vary in
abundance (Figure 4A). From this, we see that, while remdesivir sup-
pressed viral replication in Patient D, the same dose had little impact on
the viral RNA from the identical strain, Hap1_A, in Patient A (Figure 4B).
Remdesivir resistance was not found to account for the difference in
response. Instead, the variable abundance of multiple distinct haplo-
types present in different samples from Patients A, B, H, and I, including
in samples obtained from deep within the lung, is consistent with the
presence of tissue compartmentalization, wherein a pathogen replicates
in physically separated niches within the lung potentially accumulating
mutations that allow different populations to be distinguished. Diag-
nostic specimens that incompletely sample these poorly mixed virus
populations, result in mixed haplotypes that vary in frequency from
8 | BOSHIER ET AL.
sample‐to‐sample, as demonstrated in our patient data. The findings are
supported by the independent reports that SARS‐CoV‐2 viral loads vary
in different areas of lung sampled postmortem.37
Tissue compartmentalization is well described for other in-
flammatory lung infections including Mycobacterium tuberculosis and
influenza and has been associated with uneven drug penetration,
leading to poor resolution of infection and predisposing to drug re-
sistance.10,38,39 Modeling of drug levels within lung tissue from
SARS‐CoV‐2‐infected patients also suggests that remdesivir pene-
tration into lung tissue is poor.40 In Patient A, the persistence of
different viral populations at variable frequencies, including in
bronchoalveolar lavage, supports the presence of viral compart-
mentalization as potentially contributory to reduced remdesivir
effect. The rebound of viral sgRNA and RNA at the end of remdesivir
in Patients A and D, respectively also suggests a suboptimal duration
of treatment (Figures 1 and 3A). At the same time suppression of viral
RNA in Patient D may reflect higher remdesivir tissue levels seen in
neonates in which drug clearance is reduced.41 Taken together with
pharmacokinetic‐pharmacodynamic (PKPD) models of SARS‐CoV‐2
viral dynamics, which predict that greater than 90% inhibition of
replication is required to interrupt viral replication, the results pre-
sented here corroborate predictions that remdesivir (87% inhibition)
monotherapy is unlikely to succeed.42 Based on previous experience
of treating serious RNA infections in the lung, we speculate that early
treatment with combination therapy may be required for antiviral
effect.
The haplotypes we constructed for Patients A, B, H, and I were
phylogenetically sister taxa, with generally only one haplotype per
patient identical to freely circulating lineages (Figure S9). The only
outlier in this respect is Patient A, which shared a haplotype with
Patient D. It is possible that Patient A could have acquired their
haplotype through cotransmission or superinfection.34 However, on
balance, the data do not support this. Patients B, H and I were known
to be immunocompromised, while Patient A remains under
F IGURE 4 Frequency of identified haplotype over time for individual patients. (A) Haplotype frequency over time for Patients A, B, H, and I.
(B) Right: phylogenetic tree of haplotypes from Patients A and D, nucleotide mutation shown above each cluster; left: haplotype frequency over
time for Patients A and D. Black line is Ct value, red line indicates remdesivir received, black dot is sample taken, blue circle indicates sample
successfully sequenced. Bars indicate frequency of identified haplotypes
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investigation for immune dysfunction. Within‐host evolution of
stable viral haplotypes (clones) is well described for norovirus and
influenza in immunocompromised patients.43,44 Moreover, evolution
of variants in SARS‐CoV‐2 has also been described in several im-
munocompromised patients, although in the absence of haplotype
reconstruction, whether these represent multiple co‐existing geno-
types is unclear.45 We, therefore, conclude that early within‐host
evolution most logically explains the diversity seen in Patients A, B, H,
and I.
A major caveat to our findings is that of our cohort pediatric, for
which both the clinical picture and outcome of SARS‐CoV‐2 infec-
tions are known to differ from adults. Notwithstanding, similar pat-
terns of clinical and virological response to remdesivir have been
described in adults.2,7,46 Moreover, both clinical and viral sequence
data from the use of repurposed drugs to treat other severe RNA
viral infections have shown similarities in adults and children.10,38
Additionally, although the largest of its kind, our cohort is small, with
interpatient clinical and genomic heterogeneity patterns restricting
some of the conclusions that can be drawn. Nevertheless, some
observations, such as the observation of persistent viral subpopula-
tions, span several patients with different clinical prognoses. Larger
studies using deep clinical and viral profiling of multiple samples from
adult patients treated with remdesivir alone and in combination
would provide better insight.
In summary, we show that treatment with remdesivir is capable
of suppressing SARS‐CoV‐2 viral and subgenomic RNA in vivo and
demonstrate that the latter, in particular, needs further investigation
as a potential biomarker for monitoring antiviral therapy. Our data
suggest that heterogeneous response to remdesivir is not due to
resistance but rather is likely to be caused by suboptimal tissue levels.
The patterns of SARS‐CoV‐2 within‐host genetic heterogeneity un-
covered by deep sequencing may be most parsimoniously explained
by viral compartmentalization within lung‐tissue, a factor that is al-
ready known to impede drug penetration in patients with other lung
infections. This may compound inherently poor remdesivir tissue
penetration and rapid clearance of active metabolites in those with
normal renal function. We and others have shown that where com-
partmentalization occurs in influenza and M. tuberculosis, combina-
tion therapies improve outcomes.10,38 Based on our experience of
using similar drugs for the treatment of serious RNA viral infections,
we propose that a more personalized medicine approach combining
in vitro and in vivo pharmacokinetic measurements, viral RNA, and
sgRNA profiling together with viral evolutionary modeling could help
to optimize the use of remdesivir both alone and in combination for
treatment of SARS‐CoV‐2.
The COVID‐19 Genomics UK (COG‐UK)
Consortium
A full list of consortium names and affiliations can be found at
https://www.cogconsortium.uk.
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